A Phase III Study to Assess the Safety, Tolerability, and Efficacy of MK0822 (Odanacatib) in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer

Trial Profile

A Phase III Study to Assess the Safety, Tolerability, and Efficacy of MK0822 (Odanacatib) in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Odanacatib (Primary)
  • Indications Cancer metastases; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 11 Aug 2016 Planned End Date changed from 1 Aug 2008 to 1 Sep 2008.
    • 11 Aug 2016 Planned primary completion date changed from 1 Aug 2008 to 1 Sep 2008.
    • 21 Jul 2012 Additional trial location (United Kingdom) added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top